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Despite advances in bone grafting technology for musculoskeletal injury, re-
injury or incomplete healing persists.  Efforts to modify bone allografts using proteins 
and growth factors show improvement in wound healing outcomes.  This thesis uses 
FTY720, an agonist of S1P receptors 1 and 3, to improve bone graft integration through 
bone regeneration and vascularization.  Four methods of delivering FTY720 into a bone 
defect are described: 
1) FTY720 loaded onto a PLAGA-coated bone allograft and implanted in a 
critical size rat cranial defect. 
2) FTY720 loaded onto a PLAGA graft and implanted in a rat tibial defect. 
3) FTY720 loaded into a Matrigel plug and injected in a mouse tibial defect. 
4) FTY720 directly adsorbed to human bone xenografts and implanted in a 
critical size rat cranial defect. 
In each of these models, FTY720 release was characterized, and bone regeneration and 
vascularization was monitored within the defect.  Additionally, local tissue composition 
was evaluated. 
 The results presented in this thesis indicate that FTY720 released locally into the 








1.1 Clinical Need for Bone Grafting Technologies 
Each year, nearly $510 billion is spent in the United States to treat musculoskeletal 
conditions [1], amounting to nearly 2.4 million procedures in 2011 [2].  Of that, $2.5 
billion is spent on bone grafting procedures after incidents such as wartime trauma, 
accidents, bone resections, spinal fusions, and periodontal procedures [3].  As with the 
implantation of any material into the body, there are a variety of factors to consider.  
These include the biocompatibility and immunogenicity of the implant material, its 
ability to integrate with and be remodeled by the host tissue, as well as its biomechanical 
compatibility with the structure and function of the injured region [4].  In general, cortical 
bone is more load-bearing, and takes more time to revascularize than cancellous bone, 
which tends to be more porous [4].  Additionally, cancellous bone experiences creeping 
substitution, whereby osteoblasts, osteoclasts and endothelial cells can move towards the 
central mass of the graft and remodel as they go, whereas in cortical bone, osteoclasts 
first have to digest existing mineralized matrix to make way for cellular infiltration [4].  
Therefore, it is important to consider whether the injured bone is of the cortical or 
cancellous variety, which would influence which graft material would be most suitably 
applied to restore the structure and function of the injury. 
Grafts can come in the form of human bone (i.e. autografts and allografts), animal 
bone (xenografts), and can also be composed of synthetic and natural polymers [4,5,6].  
Commonly used polymers include collagen [7,8,9], poly(lactic co-glycolic 
acid)(PLAGA) [9], poly(ethylene glycol)(PEG) [9,10,11]. Strategies have been evaluated 
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in animal models of bone defects that combine both natural and synthetic materials to 
promote bone regeneration and graft integration.  
 
1.2 Autografts for Bone Repair 
Autografts are harvested from one site on the patient’s body and transplanted to another 
site to aid in wound healing.  This procedure remains the current gold standard of 
treatment for bone tissue grafting because it maintains the osteogenic cell types necessary 
for new bone formation, as well as the osteoconductive mineral matrix that guides new 
bone deposition.  Autografts are also not challenged with the risk of immune rejection or 
disease transmission, two complications commonly associated with transplants from 
other donors or cadavers.  A common source of autograft bone is the iliac crest, as it can 
provide a relatively large volume of bone without damaging the structural integrity and 
function of the source area [12].  However, the creation of a second would site on the 
patient can cause complications such as donor site morbidity and infection if the area is 
not cared for properly [13,14,15].  Additionally, the limited supply of autograft bone 
leads to complication in matching the bone graft type to the wound area.  In the table 
compiled by Brydone et.al., it is documented that different types of bone have differing 
characteristics, specifically for structural strength [16].  A more structurally porous 
cancellous bone graft may be unable to recapitulate the load bearing properties 
experienced by cortical long bone, and would therefore be less ideal to use as a graft in a 
cortical long bone injury.  The limited ability to match bone graft type with the bone type 
in the wound area makes allografts an attractive option. 
 
1.3 Allografts for Bone Repair 
Allografts are harvested from donors and cadavers, and are used extensively to repair 
bone wounds.  This bone source eliminates the creation of a second wound site on the 
patient; however, in the case of a living donor, this procedure creates a second patient.  A 
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significant advantage of using allografts in wound repair is a larger and more varied 
supply – bone material can be harvested from cadavers and donors to meet the specific 
size and structural requirements of the bone injury.   
 A variety of techniques have been developed to reduce the potential 
immunogenicity of allograft material.  Deep-freezing and freeze-drying have both been 
used to reduce the immunogenicity of the harvested tissue [17] by stripping away 
cellularized material from the mineral matrix.  However, there are still reported cases that 
these decellularized grafts still cause chronic inflammation and a non-specific immune 
response [17].  Additionally, there is some evidence that the freeze-drying process 
diminishes the mechanical integrity of the scaffold structure [18].  There has also been 
some success using these freeze-drying techniques to allow for long term storage of 
harvested allograft material [19].  The ability to harvest and bank human allograft 
material is attractive, especially in environments that experience high incidences of bone 
injury, such as a battlefield environment.  There do still exist complications in the 
allograft banking effort, as there have been reports of biological contamination on the 
grafts after long term storage, as well as residual chemical contamination on the grafts 
that originate from the sterilization process [17,19].  In order for long term banking of 
bone allografts to be possible, there are still some technologies that have to be further 
refined. 
 Even if using allografts addresses issues such as matching graft size and structure 
to the wound area, poor graft vascularization and remodeling can still lead to eventual 
graft failure due to infection and poor integration [20].  It has been observed clinically 
that massive allografts experience a 30-60% failure rate [20], and allografts in general 
lose 50% of their mechanical integrity over 10 years [21].  It is therefore vital to find 
ways to improve graft integration and vascularization to prolong the functioning lifetime 
of the graft.  The decellularization processes preserves the osteoconductive nature of the 
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mineralized scaffold, but it strips away the osteogenic potential of the resident osteoblasts 
and osteoclasts, which have to be replaced by some other means.   
 
1.4  Sphingosine 1-phosphate is a Small Bioactive Signaling Lipid in Bone 
Regeneration and Vascularization 
Sphingosine 1-phosphate (S1P) is a pleiotropic, autocrine- and paracrine-signaling 
sphingolipid that is released into the blood upon platelet activation [22].  It acts 
extracellularly by binding to a family of five high affinity G-protein coupled receptors 
(S1P1-S1P5), and it acts intracellularly as a signaling metabolite to govern a wide range of 
biological processes that play roles in wound healing.   
1.4.1 The role of S1P in bone regeneration 
In the case of decellularized allografts, it is necessary to provide local cues to recruit 
osteoprogenitor cells to the wound area in order to begin remodeling the graft.  Ishii et.al. 
demonstrated that signaling on the S1P-S1P1 axis promoted the migration of 
osteoprogenitor cells towards higher concentrations of S1P in vitro (Fig 1.1A) [23].   





S1P1deficient mice, while osteoclast attachment increases [23].  
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CX3CR1-EGFP mice, specifically looking in the bone marrow stromal cell compartment 
or at the bone surface.  They observed that pharmacological stimulation of this signaling 
axis using SEW2871, a potent S1P1 agonist, further increases the motility of 
osteoprogenitor cells out of the bone marrow, and along the S1P gradient (Fig 1.1B) [23].  
Finally, they observed that in S1P1 deficient mice, measurement of steady state bone 
volume, trabecular thickness and trabecular density were decreased, while osteoclast 
attachment was increased (Fig 1.1C) [23].  In the absence of S1P1, osteoprogenitor cells 
are not drawn back into the circulation along the present S1P gradient, and therefore 
remain in the bone tissue and mature into osteoclasts, which is observed in the increased 
osteoclast attachment and osteoclast activity in the S1P1 mice. 
 S1P was shown to increase the chemotaxis of osteoblasts and T-cells towards 
SPK1 activity as indicated by migration towards conditioned media from SPK1-
overexpressing differentiating bone marrow macrophages (Fig 1.2A,B).  The addition of 
exogenous S1P to co-culture of bone marrow-derived macrophages (BMM) and 







production in osteoblasts through PGE2 regulation (Fig 1.2C) [24].  Taken together, Ryu 
et.al. assert that BMMs produce extracellular S1P  in response to RANKL, which binds 
to S1P receptors on osteoblasts, which then upregulates COX2 and PGE2.  PGE2 further 
induces RANKL expression, leading to osteoclastogenesis (Fig 1.2D).  Increased 
osteoclastogenesis as promoted by S1P is useful for bone matrix remodeling in bone 
regeneration. 
 It has also been shown that 
mature osteoclasts exhibit increased S1P 
production via SPK1 compared to pre-
osteoclasts (Fig 1.3A,B) [25].  They also 
elucidated that mineral deposition by 
human mesenchymal stem cells (hMS) 
was decreased when Wnt activity was 
blocked using DKK, or S1P1 activity was 
blocked using an the antagonist 
PC23019, after 7 days (Fig1.3C) [25].  
Therefore, S1P signaling in concert with 
Wnt signaling is necessary for mineral 
deposition, which is an important step in 
bone regeneration.   
 Finally, S1P has been shown to 
have a role in hematopoietic progenitor cell egress from the bone marrow.  Golan et.al. 
observed that desensitization of S1P receptors using either FTY720 or DOP, which 
degrade S1P lyase, caused a decrease in the number of colony forming units from cells 
harvested from blood of wild type mice (Fig 1.4A) [26].  AMD3100 is clinically used to 
increase circulating progenitor cells; however AMD3100 treatment on SPK1 KO mice is 











KO mice is also decreased compared 
to wild type mice after AMD3100 
treatment (Fig 1.4C) [26].  They also 
observed that S1P induced SDF-1 
secretion from bone marrow stromal 
cells is reduced when S1P receptors 
are desensitized by FTY720 (Fig 
1.4D).  They assert that therefore the 
S1P signaling axis regulates 
AMD3100-induced mobilization of 
progenitor cells from the bone marrow 
via SDF-1 levels in the blood. 
1.4.2 The role of S1P in 
vascularization 
Successful bone regeneration through graft 
integration also requires vascular infiltration 
into the graft to support the cells that are 
depositing and remodeling new bone matrix.  
As reviewed by Takuwa et.al., S1P acts on 
endothelial cells to via S1P1 and S1P3 to 
activate Rac pathways to stimulate 
angiogenesis (Fig 1.5) [27].  Specifically, it 
has been found that S1P induces the formation of adherens junctions as shown by the 
increased α-catenin and VE-cadherin polypeptides in the γ- and β- catenin 
mmunoprecipitates (Fig 1.6A) [28].  Confocal imaging of VE-cadherin staining (red) 

















endothelial cells are treated with S1P (Fig 1.6B) [28].  Also, S1P activation of S1P1 is 
known to trigger an Akt-mediated pathway that results in endothelial cell migration.  
Specifically, S1P1- and S1P3- mediated migration toward S1P was significantly increased 
in CHO cells transduced with wild type Akt (Fig 1.7A,B) and Rac expression (Fig 1.7C), 
leading to the conclusion that S1P activation of an Akt pathway leads to increased actin 
assembly and cell migration (Fig 1.7D) [29].  The increasd presence of S1P, potentially  
due to increased osteoclasts in the defect area, can further amplify an S1P gradient 
toward the actively remodeling bone defect, thereby promoting endothelial cell migration 
in that direction.  S1P has also been shown to play a role in recruiting vascular smooth 
muscle cells to stabilize newly formed vasculature [30], as evidenced by the absence of 
vascular smooth muscle cells in forming vessels in S1P1 deficient embryos (Fig 1.8). 
 Olivera et.al. has shown that S1P (SPH in the figure) is upregulated in PDGF-
mediated proliferation pathways in Swiss 3T3 fibroblasts as indicated by the increased 
presence of the radiolabeled S1P (Fig 1.9) [31].  Furthermore, Guo et.al. used 
mesenchymal stem cells transfected with basic fibroblast growth factors seeded onto 
scaffolds of tricalcium phosphate to improve host-graft integration over 12 weeks (Fig 
1.10) [32].  We can conclude that S1P-induced increase of fibroblast proliferation would 




















1.4.3 The role of S1P in lymphocyte trafficking 
Successful graft integration also requires minimal immune response to the graft material, 
preventing graft rejection.  Schwab et.al. showed that increased concentration of S1P 
through inhibition of S1P lyase resulted in increased internalization of S1P1 on the 
surface of lymphocytes, thereby decreasing their egress from lymphoid organs into 
circulation (Fig 1.11) [33].     
 Two general classes of macrophages have been characterized as contributing to 
inflammation and inflammation resolution: the M1 phenotype is pro-inflammatory while 
the M2 phenotype is more anti-inflammatory and  pro-regeneration.  Hughes et.al. 
determined that S1P promotes production of the M2 macrophage through activation of 
S1P1 receptor [34].  More recently, Awojoodu et.al. showed  that  S1P also acts through 
S1P3 to preferentially recruit M2 macrophages to sites of arteriogenesis.  They show that 







macrophages were recruited into tissue from the blood when animals are treated with an 
S1P receptor-targeted drug (Fig 1.12) [35]. 
 
1.5  FTY720 is a Potent Agonist of S1P1 and S1P3 
FTY720 is a small molecule drug that is an S1P1 and S1P3 agonist.  Its status as an FDA 
approved oral treatment for multiple sclerosis [36], as well as its superior chemical 
stability and longer half-life in the body [37] compared to other growth factors makes it a 
desirable candidate for other clinical applications. 












FTY720 released from PLAGA films in a rat cranial defect has been shown to increase 
defect healing and smooth-muscle invested microvascular formation in a rat cranial 
defect (Fig 1.13) [38].  Follow up studies showed that FTY720 promoted smooth muscle 
cell investment onto forming vasculature, as well as improving the elastic modulus and 
ultimate compressive strength in a tibial defect (Fig 1.14B,C) [39].  Spatially controlled 
regeneration of bone within a cranial defect was achieved by FTY720 released from 
heterogeneously composed PLAGA microsphere scaffolds (Fig 1.15) [40].  It is evident 












formation compared to the 50:50 PLAGA side, confirming that polymer composition can 
be used to control the release rate of FTY720 in the defect .  It was also demonstrated that 
application of FTY720 in vivo significantly enhanced SDF-1α mediated chemotaxis of 
bone marrow mononuclear cells (Fig 1.16A) [41].  FTY720 is also shown to promote 
BMP-2 mediated osteoblast differentiation, as evidenced by alkaline phosphatase and 
osteocalcin staining (Fig 1.17A,B) [42].  They also observed increased Smad 1/5/8 and 
ERK 1/2 phosphorylation in C2C12 cells, indicating differentiation down an osteoblastic 














 Finally, the local release of FTY720 from PLAGA films in a dorsal skinfold 
window chamber produced up to a 153% increase in local microvascular length density s 
well as increased smooth muscle investment after 7 days (Fig 1.18A,B) [43].   Imaging of 
the spinotrapezius muscle on the back of a mouse after treatment with PLAGA or 














1.5.2 Application of FTY720 for local immunosuppression 
Successful graft integration also requires reduced immune response to the implant 
material.  Local activation of FTY720 is shown to have immunosuppressive effects, 
which has been demonstrated by inhibition of lymphocyte recirculation (Fig 1.19 and Fig 
1.20) [44,45]. 
 Furthermore, a 
decreased leukocyte presence is 
observed in defects that contain 
FTY720-releasing graft as 
evidenced by decreased CD45 
staining (Fig 1.14A) [39].  
Additionally, FTY720 release 
from PLAGA nanofibers in a 
dorsal skinfold window 
chamber generated a smaller 
fibrous capsule compared to unloaded fibers, which 
indicates a diminished immune response around the 
implant (Fig 1.16B) [41].  Subsequent application of 
FTY720-loaded PLAGA nanofibers into a 
mandibular bone defect in Sprague Dawley rats 
increased the recruitment of M2 anti-inflammatory, 
pro-regenerative macrophages (Ly6CloCD206+ 
cells), promoting bone deposition in the defect (Fig 
1.16C) [41].  It has been shown that FTY720 in 
combination with cyclosporin A improved graft 











and by reducing CD4+ and CD8+ T cells in circulation ten days after graft transplantation 
(Fig 1.21E) [46]. 
 The immune-protective properties of FTY720, in addition to its roles in increasing 
bone cell recruitment and vascularization makes it an ideal candidate for use in bone 
wound regeneration. 
 
1.6  Poly(lactic co-glycolic acid) as a Biomaterial for Bone Repair 
Poly (lactic-co-glycolic acid)(PLAGA) is a widely used synthetic material for 
medical applications due to its high biocompatibility and low immunogenicity and 
toxicity [47], its highly customizable physical and mechanical properties [49,50,51], and 
its approval for use by the Food and Drug Administration (FDA) makes it a promising 
technology for clinically translatable applications [50].  For bone regeneration, PLAGA 









bone injury [49,51,52,53,54].   Further studies show that augmentation of synthetic 
materials, often with growth factors such as vascular endothelial growth factor (VEGF) 
[6,55,56], bone morphogenetic factor (BMP) [57,58], and others, often times improves 
bone regeneration within and revascularization of the defect area.  Some concern over the 
supra-physiological doses of BMP to achieve bone healing causing undesired bone 
formation encourages exploration of other therapeutic agents [59].    In the past, we have 
used FTY720, a small molecule with agonist activity at receptors S1P1, and S1P3-5, 
released from scaffolds composed of PLAGA placed within critical sized bone defects to 
promote bone regeneration and vascularization [38,39,40,41,43,60]. 
Despite the many published instances of PLAGA applications  in animal models, 
and its status as an FDA-approved material, only a very small fraction of those 
technologies have reached clinical trials, and only a select few of those PLAGA based 
medical technologies are commercially available for use to treat bone injuries, or for drug 
or cell delivery.   A survey of PLGA based technologies in clinical trials include a bone 
graft by ISTO Technologies composed of  PLGA/hyaluronic acid and bone,[61,62,63], 
and a resorbable bone screw that releases ciprofloxacin and performs superior to titanium 
screws in preventing bacterial infection [64].  Boston Scientific Corporation has an 
ongoing phase III clinical trial for a coronary stent partially composed of PLAGA, called 
the Synergy [65,66,67], and preliminary study results indicate successful drug elution 
from the stent over the course of 30 days  .  Yet this is a very small number of clinical 
trial studies compared to the number of published PLAGA-containing implant 
technologies that are developed and tested in animal models. 
One potential concern is that nanoscale PLAGA-based delivery vehicles 
accumulate preferentially in the liver, which may cause toxicity [47].  Furthermore, 
empty PLAGA nanoparticle administration to Balb C mice to evaluate blood-brain 
barrier permeability appeared to cause otherwise unexplained sedation and pain to the 
animals [68]. However, nanoscale particles convey desirable targeted drug delivery 
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characteristics by being more invisible to the immune system.   Additionally, the widely 
tunable drug release kinetics and mechanical properties may require further 
characterization and testing before use in human subjects [69].  
 
1.7 Specific Aims Addressed in this Thesis Project 
The studies presented in this thesis set forth to address two specific aims. 
1.7.1 Evaluating the efficacy of topically applied FTY720 for bone regeneration in a 
sub-critical tibial defect 
FTY720 has been incorporated previously in PLAGA coatings of bone allografts, and 
was shown to promote bone regeneration. Objective 1 of this aim is to develop a local 
delivery system for FTY720 in a tibial defect model.  The delivery vehicle of choice is a 
polymer plug composed of Matrigel, a basement membrane-derived polymer.  Objective 
2 of this aim is to use the delivery system from objective 1 in an animal model of a long 
bone defect, specifically in the tibia of a mouse.  The development of this model would 
be valuable in allowing future use of transgenic mouse models to more closely 
interrogate different processes and cell functions involved in wound repair that are less 
feasible in rat models of tibial defects.  The efficacy of the FTY720 treatment will be 
evaluated using X-ray imaging as well as uCT imaging to measure bone regeneration. 
1.7.2 Evaluating the efficacy of FTY720 adsorbed directly to the surface of a human 
bone allograft for bone regeneration in a critical sized cranial defect 
Previous work has released FTY720 from a PLAGA-coated bone allograft to promote 
bone regeneration and vascularization in the defect area.  Objective 1 of this aim will be 
to develop and implement a PLAGA-free strategy to apply FTY720 to bone grafts.  This 
will be accomplished by quantifying the release and activity of FTY720 from a bone graft 
using HPLC/MS.  Objective 2 of this aim is to apply the polymer-free bone graft 
developed in objective 1 into a critical size cranial defect created in Sprague Dawley rats.  
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uCT imaging and analysis will be employed to measure bone formation and 
vascularization.  Objective 3 will evaluate the tissue composition and the immune 
response to the bone allograft through immunohistochemical staining of harvested tissue. 
 
1.8 Organization of Thesis 
Several studies were conducted to evaluate the efficacy of locally delivered FTY720 on 
promoting bone regeneration and graft integration in defect models.  Chapter 2 describes 
both the in vitro methods, the animal models used, and the methods of analysis employed 
to evaluate bone regeneration and vascularization.  Chapter 3 will present the results and 






 Several in vitro and in vivo models were used to evaluate the efficacy of locally 
delivered FTY720 on promoting bone regeneration and graft integration. 
 
2.1  Locally Applied FTY720 Accelerates Healing of Critical Size Cranial Defect 
We have previously published that local delivery of 
FTY720 via PLAGA degradation from a bone 
allograft in a rat critical size cranial defect accelerated 
graft integration compared to unloaded grafts [60].  
The defect used to evaluate healing was circular in 
shape, and a semi-circular implant was placed in one 
half of the defect space.  This model allowed us to 
evaluate both host-graft bridging on the graft side, as 
well as directed bone growth from the host bone 
towards the graft in the void space (Fig 2.1).  This 
model was employed to evaluate bone deposition and 
vascularization over  weeks.  The methods below are 
summarized from Huang et.al. [60]. 
2.1.1 Evaluation of FTY720 release from PLAGA and FTY720 bioactivity 
FTY720 and 50:50 PLAGA polymer were dissolved into 1:12 (w/w) dichloromethane.  
Cranial allografts were harvested from Sprague Dawley rats and were placed in the drug: 











lyophilized to remove residual solvent.  To measure encapsulation efficiency, the coated 
grafts were sonicated in chloroform to dissolve the PLAGA layer.  The samples were 
taken through sphingolipid extraction.  Briefly, D-erythro-Sphingosine (C-17 base) is 
added to the dissolved PLAGA and the solution is dried to a solid using nitrogen flow.  
Immediately prior to HPLC/MS analysis, this pellet was dissolved in methanol.   To 
measure FTY720 release, the grafts were placed in vials of SBF (pH 7.2; 7.996g NaCl, 
0.35g NaHCO3, 0.3g KCl, 0.136g KH2PO4, 0.095g MgCl2, 0.278g CaCl2, 0.06g MgSO4 
in 1L deionized water).  The grafts were moved into clean vials of SBF daily, and the 
solution from the previous day was kept for sphingolipid extraction and HPLC/MS.   
 Additionally, the bioactivity of the released FTY720 was validated using a 
sphingosine kinase 2 (SPK2) assay developed by our collaborators in Dr. Kevin Lynch’s 
lab at the University of Virginia.  It is reported that SPK2 phosphorylates FTY720 into its 
active form FTY720-P in vivo [60].  The in vitro assay uses purified SPK2 and a 
radiolabeled 32P-ATP to determine of SPK2 would phosphorylate the FTY720 released 
from the PLAGA coating.  This was measured in a Beckman Coulter LS 6500 liquid 
scintillation counter. 
2.1.2 Creation of critical size cranial defect implanted with PLAGA-coated graft 
Animals received either graft with no PLAGA coating (uncoated), a graft with PLAGA 
coating (coated), a graft coated 1:200 w/w FTY720:PLAGA (low FTY720) or a graft  
coated with 1:40 w/w FTY720:PLAGA (high FTY720).  Briefly, the dorsal skin was 
sterilized and a longitudinal incision was made over the dorsum of the skull over the 
sagittal suture through the skin and periosteum.  The periosteum was elevated and 
reflected laterally.  A 3mm round burr was used to create a 9mm defect in the bone under 
constant saline irrigation using a Hall High Speed Drill (CONMED, Linvatec, Largo, 
FL).  The semicircular graft was placed underneath the periosteum, in direct contact with 
the parietal bone, centered on the sagittal suture and between the coronal and lamboid 
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sutures.  The periosteum and skin were sutured shut, and animals were given Ketoprofen 
(3mg/kg SC) for three days post surgery to minimize pain.  Rats were given free access to 
food and water, and were monitored for complications or abnormalities.   
At each time point, animals were placed in the uCT and scanned in air with the 
following parameters: 38 μm voxel size, 55 kVp, 145 μA, medium resolution, 38.9 mm 
diameter field of view, and 200 ms integration time (73 mGy radiation per scan).  The 
threshold for bone evaluation was set at 481.3mg hydroxyapatite (HA)/cm3.  Each 
animal’s scans maintained the same number of slices (≈260 slices) for the entire study, 
centered at the defect, with equal extension in the anterior and posterior directions from 
the edges of the defect.  Regions of interest were drawn on the 2D image slice, and were 
bounded by the physiological ridges that separate the parietal bone from the temporal 
bone, resulting in the inclusion of all the parietal bone through the slices. 
2.1.3 MICROFIL perfusion of wound area for uCT evaluation 
At week 8, after uCT imaging for bone growth, cranial blood vessels were perfused with 
MICROFIL, a radio-opaque solution, to allow for imaging and quantification of vessel 
growth by uCT.  Briefly, the rats were euthanized and the heart was exposed.  The 
common carotid arteries were cannulated, and a small incision was made in the right 
atrium of the heart to allow blood drainage.  The arteries were then ligated directly 
beneath the cannulation points to allow perfusion of the head region with a heparin-saline 
solution to push the blood out of circulation.  Then, 3mL of MICROFIL was perfused 
from each artery over 5 minutes.  The solution was allowed to set for 16 hours at 4°C, 
after which the area surrounding the parietal bone was harvested, fixed and decalcified.  
Following decalcification, samples were scanned in are with the following parameters: 
21μm, 45kVp, 177μA, medium resolution, 21.5 mm diameter field of view and 200ms 
integration time.  Vasculature was thresholded from decalficied tissue using 164-1500 
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HA/cm3 and the sagittal sinus was excluded from analysis due to its large and varying 
size between animals. 
 
2.2  Locally Applied FTY720 for Graft Integration in Chimeric Tibial Defect 
While cranial size critical defects are supremely useful for investigating bone defects in a 
non-load bearing environment such for craniofacial applications, it was also important to 
evaluate how FTY720 treatment improves graft integration in load bearing injuries.  We 
are also interested in the origin of the various cells that contribute to the wound healing 
process.  In order to begin addressing these questions, we use a tibial defect model 
created in chimeric eGFP Sprague Dawley rats to probe the source of cells that contribute 
to wound healing, while also investigating the mechanical integrity of the FTY720-
treated graft. 
2.2.1 Creation of tibial defect implanted with PLAGA graft  
Rats were lethally irradiated with 10 grays over 2 hours to deplete their native bone 
marrow.  Subsequently, bone marrow harvested from eGFP rats was transplanted into the 
irradiated rats and allowed to engraft over 5 weeks, as shown in Fig 2.2.  In this manner, 
all future cells that come from the bone marrow would constitutively express GFP, 
allowing us to monitor the source of cells contributing to regeneration in the defect. 
 Segmental tibial defects were surgically created in the right hind limb of each 
eGFP chimera. Rats were given one of three treatments in the right hind limb: allograft 
alone (c), PLAGA-coated allograft (p), and PLAGA-coated allograft containing FTY720 




2.2.2 Mechanical testing of rat tibia  
After twelve weeks, both the unfractured left hind limb, which served as the contralateral 
control, and the experimental right hind limb were harvested for mechanical evaluation.  
Using a Bose Endura TEC ELF 3220 system, the distal end of the tibia was held in a 
fixed position, while a constant rotation of 3°/second was applied to the proximal end of 
the tibia until the bone fractured.  The maximum torsional force was recorded, as well as 
the rotation of the proximal end at failure.  It was observed that all graft failures occurred 
at the interface of the graft and host bone.   
2.2.3 Histological evaluation of tissue  
Tissue was harvested from the wound area at 12 weeks.  Sections were stained with GFP 
and CD90 to determine whether CD90+ progenitor cells were also positive for GFP.  Co-
staining indicated the recruited cells originated in the bone marrow. 
 
2.3  Topically Applied FTY720 for Bone Regeneration in a Sub-Critical Tibial 
Defect 
Here, we describe a sub-critical tibial defect model that was developed in mice, which we 
hope will allow us to take advantage of the various opportunities to create transgenic 
mouse models that would allow closer inspection of cellular processes involved in wound 
healing that are not feasible in rat models.  This thesis will describe the model, as well as 
the development of a strategy to locally deliver an injectable, FTY720-loaded vehicle 
into a sub-critical tibial defect where no bone graft is used.  Without a bone graft in place, 
the cues provided by the mineralized matrix are removed, and any mechanical support 
provided by the graft scaffold is removed as well.  Instead, we inject a viscous Matrigel 
plug loaded with FTY720, which then hardens at body temperature. 
2.3.1 Creation of tibial defect 
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A tibial defect was created in Balb/C 
mice using a Bonnerans-Einhorn device, 
pictured in Fig 2.3.  Briefly, an incision 
was made over the knee, and a sterile 
metal pin was inserted into the medullary 
canal.  Mice were placed on the holder of 
the Bonnerans-Einhoren device, and a 
220g weight was dropped from a height 
of 40cm onto a blunt blade in contact with the tibia.  0.1mL of Matrigel was injected into 
the defect area of each animal.  Animals were sorted into three groups: 1) no drug, 2) 
1nM FTY720 (low) in Matrigel, and 3) 10nM FTY720 (high) in Matrigel.  The Matrigel 
was viscous as room temperature, and hardened into solid plugs at body temperature. 
 The metal pin inserted into the medullary canal interfered with the uCT imaging, 
so therefore two methods were employed to image the tibial defects.  Every week, all 
mice were imaged by X-ray, using a 1 minute exposure time at 30eV.  At each time point, 
some animals were euthanized and the hind limbs were harvested.  The pin was removed, 
and the limbs were imaged by uCT in air using medium resolution and voxel dimensions 
of 0.21μm. 
 
2.4  Locally Applied FTY720 Adsorbed Directly to Surface of Human Bone Graft in 
Critical Size Cranial Defect 
FTY720 has been described to have immunosuppressive properties when applied locally.  
To investigate this in a bone defect environment, as well as the evaluate the potential to 
eliminate the polymer phase in the drug delivery vehicle, we directly adsorb FTY720 to 






2.4.1 FTY720 drug loading onto and release from human trabecular allograft 
Human trabecular grafts were received from collaborators at Lifenet Health.  The grafts 
were washed in their proprietary Allograft XG to remove cellular debris.  FTY720 was 
fully dissolved into methanol, and the graft was placed inside to allow drug to adsorb.  To 
measure loading efficiency, the pre- and post-loading methanol solution was saved for 
sphingolipid extraction.  Briefly, D-erythro-Sphingosine (C-17 base) is added to the 
dissolved PLAGA and the solution is dried to a solid using nitrogen flow.  Immediately 
prior to HPLC/MS analysis, this pellet was dissolved in methanol.   To measure FTY720 
release, the grafts were placed in vials of SBF (pH 7.2; 7.996g NaCl, 0.35g NaHCO3, 
0.3g KCl, 0.136g KH2PO4, 0.095g MgCl2, 0.278g CaCl2, 0.06g MgSO4 in 1L deionized 
water).  The grafts were moved into clean vials of SBF daily, and the solution from the 
previous day was kept for sphingolipid extraction and HPLC/MS.   
2.4.2 Creation of critical size cranial defect 
Female Sprague-Dawley rats (6-8 weeks) underwent a critical size (8mm) defect surgery, 
as illustrated in Fig 2.1.  Briefly, the dorsal skin was sterilized and a longitudinal incision 
was made over the dorsum of the skull over the sagittal suture through the skin and 
periosteum.  The periosteum was elevated and reflected laterally.  A 3mm round burr was 
used to create a 9mm defect in the bone under constant saline irrigation using a Hall High 
Speed Drill (CONMED, Linvatec, Largo, FL).  The semicircular graft was placed 
underneath the periosteum, in direct contact with the parietal bone, centered on the 
sagittal suture and between the coronal and lamboid sutures, and the periosteum and skin 
were sutured shut.  
 The animals received one of three treatments (n=6): no implant, human trabecular 
semicircular bone graft (graft-only), and FTY720-loaded human trabecular semicircular 
bone graft (graft + FTY720).  The FTY720 was adsorbed directly to the bone grafts as 
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previously described.  The grafts were analyzed and distributed evenly among the two 
graft groups to control for graft size and density variation. 
 uCT will be used to evaluate bone formation every two weeks.  Briefly, rats were 
imaged in air using the following parameters: 38 μm voxel size, 55 kVp, 145 μA, 
medium resolution, 38.9 mm diameter field of view, and 200 ms integration time (73 
mGy radiation per scan).  The threshold for bone evaluation was set at 481.3mg 
hydroxyapatite (HA)/cm3.  Each animal’s scans maintained the same number of slices 
(≈260 slices) for the entire study, centered at the defect, with equal extension in the 
anterior and posterior directions from the edges of the defect.  Regions of interest were 
drawn on the 2D image slices.  In the cranial defect, the region of interest was bounded 
by the physiological ridges that separate the parietal bone from the temporal bone, 
resulting in the inclusion of all the parietal bone through the slices. 
2.4.3 MICROFIL perfusion of wound area for uCT evaluation 
uCT will also be used to evaluate vascularization of the defect region.  At weeks 2 and 
12, after in vivo imaging for bone formation, animals will be euthanized for the purposes 
of vascular visualization in the microCT.  Briefly, the common carotid arteries will be 
cannulated.  The vasculature will be flushed with 10 mL 2% heparin-saline, then filled 
with 3 mL MICROFIL© injected simultaneously through both arteries, and allowed to 
set for 16h at 4°C.  The top of the skull will be harvested, fixed, and decalcified.  The 
following microCT parameters were used previously to scan the microvasculature in air: 
21 μm voxel size, 45 kVp, 177 μA, medium resolution, 21.5 mm diameter field of view, 
200 ms integration time, and threshold of 164-1500 mg HA/cm3.  Similar to bone 
analysis, 2D contours will be drawn to enclose the area of interest, excluding the sagittal 
sinus because of its large volume compared to other microvasculature, and due to the 
large variance of its size between samples.  Additionally, this analysis will be split along 
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the sagittal sinus to allow comparison between vasculature in the empty defect space 
(void side) and the side containing the graft (graft side). 
2.4.4 Histological evaluation of tissue 
At the final timepoint tissue sections were taken for histological analysis.  Sections were 
stained for Hematoxylin & Eosin, as well as Massons Trichrome to evaluate tissue 
composition.  Additional immunohistochemical and immunofluorescence staining was 
performed using CD90 to label osteoprogenitor cells, CD29 to detect bone marrow 









3.1 Locally Applied FTY720 Accelerates Healing of Critical Size Cranial Defect 
As described in Chapter 2, a critical size cranial defect was employed to evaluate the 
effect of locally released FTY720 from a PLAGA-coated bone allograft on bone 
regeneration and vascularization. 
3.1.1 FTY720 release from PLAGA coating maintains bioactivity 
We showed that about 50% of the total loaded FTY720 was released into the SBF, and 
the activity profile indicates that the FTY720 released from the graft could be 
phosphorylated by SPK2 (Fig 3.1) [60].  Drug release is governed by PLAGA 
degradation from the graft, and the entirety of the PLAGA coating would be expected to 








3.1.2 FTY720 promotes total bone 
growth 
FTY720 treated groups showed almost 
complete graft-host integration on the 
graft side of the defect, as well as 
directed bone growth within the void 
space (Fig 3.2A) [60].  Bi-weekly 
quantification of bone growth revealed 
that the higher dose FTY720 
accelerated new bone formation in the 
first two weeks, but by 8 weeks both 
the low and high dose FTY720 
groups exhibited similar levels of 
total bone formation (Fig 3.2B). 
3.1.3 FTY720 promotes graft 
integration through vascularization 
FTY720 did not have a significant 
effect on increasing total vessel 
growth.  However, we observed that 
the control groups had particularly 
poor vessel infiltration into the graft, 
but the FTY720 groups show vessel 
formation in the plane of the graft 
and periosteum.  When quantifying 



















MICROFIL-assisted uCT analysis, or from assessment of αSMA histology of cranial 
tissue sections for smooth muscle investment around vasculature, the total amount of 
vessel growth was not significantly different between groups at week 8 (Fig 3.3).  
However, the FTY720 treated groups appear to have improved blood vessel investment 
into the graft. 
 
3.2  Locally Applied FTY720 for Graft Integration in Chimeric Tibial Defect 
As described in chapter 2, an eGFP chimeric rat was created to evaluate the origin of 
cells recruited to the tibial defect.  Firstly a differentiation assay was used to confirm the 
multipotency of cells in the chimeric bone marrow, as shown in Fig 3.4.  With this 
confirmation, we were able to use the chimeric rat model to evaluate the origin of cells 
recruited to the defect area to participate in wound healing. 
3.2.1  FTY720 increases mechanical strength of soft tissue 
We observe that FTY720 released from PLAGA increases soft tissue toughness by 6 
times compared to the unfractured contralateral control in the untreated group (control 
c)(Fig 3.5B).  Additionally, the bone could withstand more rotation before failure as 
compared to control c (Fig 3.5B).  The toughness of the bone itself remained unchanged 
across all groups.  We have previously observed that application of FTY72 increases 
vascularization in the graft [60]; this may be anchoring the graft more firmly into the 
defect space compared to unloaded graft, which is contributing to the higher rotation 





higher amounts of soft tissue 
formed around the graft 
interface.  It has been shown that 
FTY720 increases osteoblast 
differentiation; it is possible that 
the increased osteoblast presence 
leads to increased deposition of 
collagen that has not been 
remodeled into mature bone.  
Reports show that collagen fibers 
are more elastic compared to 
mineralized bone, so it would 
make sense that the more pliable 
soft tissue is more plastic 
compared to mineralized bone 
[71].   
3.2.2 FTY720 increases recruitment of progenitor cells from the bone marrow 
Histological staining was performed to determine the origin of cells recruited to the 
defect area.  
Analysis revealed 
that in groups 
treated with 
FTY720, there was 
an increased 












osteoprogenitor cells compared to untreated and PLAGA only groups (Fig 3.6). 
Additionally, it appears that the eGFP+CD90+ cells are infiltrating the graft area as 
indicated by the dotted line (Fig3.6).  Cells that are labeled gray are cells that are positive 
for both markers, indicating they came from the bone marrow. 
3.3 Topically Applied FTY720 for Bone Regeneration in a Sub-Critical Tibial Defect 
A large number of bone defects are not suited for implantation of a bone graft.  
Additionally, non-union healing occurs in about 10% of the 7.9 million annual bone 
fracture incidences [72].  To that end, we set out to develop an injectable, graft free 
strategy using freely diffusing FTY720 to promote healing in sub-critical tibial defects.  It 
can be seen that at two weeks, FTY720 appears to accelerate the increase of bone volume 
in the defect area, though by four weeks all four groups appear to have the same bone 
volume (Fig 3.7A).  FTY720 appears to accelerate the formation of the fracture callous, 
as evidenced by the decrease in bone density of the FTY720 groups at two weeks (Fig 
3.7B).  The bone density rises by four weeks as the fracture callous is remodeled, which 
can be seen in the X-rays in Fig 3.7A.  It is established that fracture healing in particular 
occurs in two general phases: first, a bony callous is formed to provide temporary 
mechanical stability to the defect, then cells migrate into the defect area to remodel the 
callous and deposit more mineral to achieve cortical union between the two ends of the 
defect [73,74].  The application of FTY720 appears to accelerate the formation of the 
fracture callous, and the uCT reconstructions in Fig 3.7B indicate that the treated groups 
achieved cortical union at four weeks whereas the untreated group did not.  It has been 
shown that FTY720 enhances BMP-2 mediated osteoblast differentiation [42] and that 
FTY720 significantly enhances SDF-1α mediated chemotaxis of bone marrow 
mononuclear cells [41], both of which likely contribute osteogenic cells to deposit and 




3.4  Locally Applied FTY720 Adsorbed Directly to Surface of Human Bone Graft in 
Critical Size Cranial Defect 
3.4.1 Sustained released of FTY720 directly adsorbed to human trabecular bone 
continues over 4 weeks 
As described, FTY720 was adsorbed directly to the surface of human trabecular bone 
grafts.  Quantification of pre- and post-loading solutions showed an average drug loading 
of 193ug FTY720/mm3 bone graft, with a loading efficiency of 90% (Fig 3.8A).  FTY720 
release is sustained over four weeks, with a burst release in the first three days followed 








from the surface of the bone graft, and the linear profile suggests this release is limited by 
diffusion from the surface.  The continued release could be attributed to the release of 
FTY720 from the bulk mass of the graft.  Previous incarnations of this graft used a 
PLAGA coating to load FTY720 to the bone allograft, and saw a 10-fold lower loading 
efficiency (Fig 3.1B).  FTY720 loading efficiency was limited by the dissolution of 
FTY720 in the PLAGA solution, whereas here FTY720 loading efficiency is only 
dependent on the surface area of the graft itself, as well as the drug molecule’s ability to 
bind to itself.  While drug release was driven by PLAGA degradation in the PLAGA-
coated graft, here it is driven by direct diffusion off the surface of the graft into the defect 
environment. 
3.4.2 Local release of FTY720 from human trabecular bone facilitates increased 
graft integration over 12 weeks 
Bone deposition was evaluated bi-weekly using uCT analysis.  As shown in Fig 3.9A, 
FTY720 increases bone regeneration, both in bridging the graft to the edge of the defect, 
as well as depositing bone in the void space.  Bone volume is shown to increase with 
increasing release of FTY720 from the graft, as shown in Fig 3.9D, and bone volume is 
consistently higher in defects treated with FTY720 compared to grafts without.  In 
addition to a positive linear correlation between drug release and bone volume increase, 





released (Fig3.8B), suggesting there may be an optimal dose for accelerated bone 
formation at the higher drug dose.  It also appears that bone deposition may occur 
preferentially within the void space; we observe that while bone volume steadily 
increases over 12 weeks, bone density experiences a downturn after week 10 (Fig 3.9 
B,D).  Newly formed bone that is deposited in the void space would likely be less dense 
compared to mineral deposition within the graft structure itself. 
 Huang et.al. observed an overall higher magnitude of bone growth in the cranial 
defect, but also observed a smaller amount of released FTY720 [60].  It is possible that 
although FTY720 promotes bone regeneration and vascularization, there is a saturation 
limit for FTY720, and once reached, there is no further augmentation of wound repair.  
The new results presented here could inform a maximum required dose to achieve graft 
integration, and therefore potential costs of therapy could be reduced by lowering the 
necessary drug loading. 
 Representative uCT images of MICROFIL perfused animals show vascularization 
within the defect area (Fig 3.10A).  Specifically, we observe increased vascularization on 
the graft side compared to the void side, suggesting improved integration of the graft with 
the host bone (Fig 3.10B), which would improve the overall lifetime of the implant in the 
defect area. 
 It is well documented that integration of the graft with the host is necessary for 
healing to occur, both through neovascularization and bone graft resorption [22, 75].  In  
clinical trial using an rh-BMP2 releasing sponges in human tibial fractures, 23% of the 
human subjects experienced treatment failure due to lack of graft integration [76].  
Previous work has shown that FTY720 promotes increases vascular diameter expansion 
and length density when locally applied in a mouse dorsal skinfold window chamber [43, 
77], and within cranial defect models [38,60].  Here, we show that FTY720 facilitates 
higher vascularization within the graft compared to in the void space, indicating 









3.4.3 FTY720 recruits progenitor cells to the defect area 
Massons Trichrome and  hematoxylin and eosin staining allow visualization of the tissue 
composition of the wound area.  It is apparent that the addition of the graft improved 
bone deposition in both the graft and void side compared to the empty and graft only 
defects (Fig 3.11).  By twelve weeks, the pores in the human trabecular graft in the 
FTY720 group have begun filling with new bone mineral, whereas in the graft only group 
the pores still appear empty.  Immunohistochemical staining (Fig 3.12) was performed, 
and images were taken in three regions as indicated by the figure: firstly, in the bridge 
region between the graft and host bone, second in the middle of the graft region, and 
third, in the center of the void space.  Staining revealed that FTY720 qualitatively 
increased the amount of CD90 and CD29 positive osteoprogenitor cells in the defect 
compared to the graft only group.  Additionally, there is an increase in CD34+ 
endothelial cells in the drug treated group.  Finally, we see a qualitative decrease in 
CD68+ macrophages in the drug treated group, suggesting possible immunosuppression 
with application of FTY720.  All these observations are still qualitative, and require 
























There remains a clinical need for effective therapies for bone regeneration and graft 
integration for a variety of bone defects.  Autografts remain the gold standard because of 
their low immunogenicity, as well as their high osteoconductivity and osteoinductivity.  
However, there still remains the complication that autograft bone material is scarce, and 
harvested autograft bone may not have the size or structural compatibility with the wound 
area.   
 The studies in this thesis present the use of FTY720 to improve the 
osteoconductivity and osteoinductivity of bone allografts.  The release of FTY720 from 
PLAGA-coated bone allografts in rat cranial defects, from PLAGA-grafts in rat tibial 
defects, from Matrigel plugs in mouse tibial defects, and from direct adsorption onto 
human bone xenografts in rat cranial defects is shown to improve bone regeneration in 
the defect area.  Additionally, vascularization into the graft is increased, indicating 
improve graft integration compared to treatments containing no FTY720.  Finally, it is 
demonstrated that FTY720 creates a local immunosuppressive environment when a 
decellularized human graft is implanted into a rat defect model. 
 For future consideration of applying FTY720 for bone regeneration in a clinical 
setting, an effort was made to remove the PLAGA component from the drug-loading 
strategy onto grafts.  A survey of literature and current available treatments show that 
despite the large number of PLAGA-based technologies used in animal studies for bone 
regeneration and other therapies, a much smaller number of those technologies reach 
clinical trials.  Therefore, we evaluated a drug-loading strategy onto bone grafts that did 
 41
not require a PLAGA component to facilitate binding of FTY720 to the graft surface and 
saw that it performed as well as a similar graft that did contain PLAGA.   
 In conclusion, the results in this thesis show that FTY720 is efficacious in 
improving bone regeneration and vascularization in bone defects, reduces 
immunogenicity of foreign grafts, and that FTY720 can be loaded onto bone grafts 
without the use of a polymer phase.  As we begin to  more thoroughly characterize the 
origins of the cells that are recruited to the wound area by FTY720, improved 
immunohistochemical, and possibly flow based methods will need to be developed and 
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